Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-month weekly isoniazid + rifapentine versus 9-month daily isoniazid for latent tuberculosis infection
ACTRN12613000599774Phase 4Completed
- Sponsor
- Melbourne Health
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of isoniazid and rifapentine in latent tuberculosis infection (LTBI) (2 arms), sponsored by Melbourne Health. Primary endpoint: Cost-benefit per completed course of preventive therapy. Started Dec 2013; status: completed.
02
Drugs
isoniazidrifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ACTRN12613000599774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000599774.